Science & health
UK approves gene-editing treatment Casgevy for eligible children aged five and older
The UK Medicines and Healthcare products Regulatory Agency has extended Casgevy’s authorisation to eligible children aged five and older with severe sickle-cell disease or transfusion-dependent beta-thalassemia. The treatment edits a patient’s bone-marrow stem cells so they can produce functioning haemoglobin, after conditioning therapy and laboratory processing. It was previously authorised for patients aged 12 and older. The regulator cites its assessment of safety, quality and effectiveness and says it will continue monitoring the treatment.
Editorial summary · Publisher article
What matters
- The conditions can cause severe anaemia, pain, infections and recurring transfusions.
- Patients’ stem cells are collected, edited in a laboratory and infused back after conditioning.
- Treatment can involve nausea, fatigue, fever, infection risk and hospitalisation while cells establish.
- The authorisation extension was granted on 29 October 2026.
Context & caveats
- Eligibility is limited to patients meeting the authorisation criteria, and the announcement does not provide outcome data for the newly eligible age group.
Why this made the edition
The regulator announcement reports a material treatment-access expansion for children with serious inherited blood disorders and explains the treatment pathway, eligibility and known risks.
Source material